Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Most relevant
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ASTELLAS PHARMA INC.
2019ASTELLAS PHARMA : Hypercholesterolemia drug repatha« sc injection receives suppl..
PU
2019Otsuka Chemical Co., Ltd. acquired part of the Cefixime Business from Astella..
CI
2019ASTELLAS PHARMA : and Seattle Genetics Announce Antibody-Drug Conjugate Enfortum..
PU
2019U.S. Fda Approves Astellas Pharma Inc.'S Supplemental New Drug Application Ad..
CI
2019Astellas Pharma Inc. Announces Results from the Phase 4, 12-Week Plus Trial, ..
CI
2019Astellas Pharma Inc. Reports Consolidated Financial Results for the Full Year..
CI
2019Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe
RE
2019Astellas Pharma Inc. Announces Executive Promotions
CI
2019Astellas Pharma Inc. Announces Results from the Phase 3 Admiral Clinical Tria..
CI
2019Actinium Pharmaceuticals, Inc. Successfully Completes the Second Module of it..
CI
2019ASTELLAS PHARMA INC : Ex-dividend day for final dividend
FA
2019Astellas Pharma Inc. Presents Fezolinetant Phase 2b Clinical Trial Results
CI
2019Astellas Pharma Inc. Announces Oral Jak Inhibitor Smyraf« Tablets Approved in..
CI
2019Tranche Update on Astellas Pharma Inc.'s Equity Buyback Plan announced on Jan..
CI
2019Astellas Pharma Inc.'s Equity Buyback announced on January 31, 2019, has expi..
CI
2019NapaJen Pharma and Astellas Pharma Establish Research Collaboration for Disco..
CI
2019Astellas Pharma Inc. Announces Executive Promotions and New Hire in Legal, IP..
CI
2019Astellas Pharma Inc. Announces Acceptance of XOSPATA (gilteritinib) for Regul..
CI
2019Cash-hoarding Japanese firms please investors as share buybacks hit record
RE
2019Affinivax, Inc. Announces Initiation of Phase 1/2 Clinical Study of ASP3772, ..
CI
2019Pfizer Inc. and Astellas Pharma Inc. Announce Results from the Phase 3 ARCHES..
CI
2019Astellas Pharma Inc. authorizes a Buyback Plan.
CI
2019Astellas Pharma Inc. Reports Consolidated Earnings Results for the Nine Month..
CI
2019Astellas Pharma Inc. announces an Equity Buyback for 40,000,000 shares, repre..
CI
2019Astellas and KM Biologics Announce Expiration of Distribution Agreement for H..
CI
2019Actinium Pharmaceuticals, Inc. Successfully Completes First Module of Collabo..
CI
2019Astellas Pharma Inc. and Astrazeneca K.K. Announce the Sale and Distribution ..
CI
2019Astellas Announces Executive Changes
CI
2019Amgen Astellas Biopharma K.K., Astellas Pharma Inc. and UCB Japan Receive Jap..
CI
2019Astellas Announces Approval in Japan for the Treatment of Prostate Cancer, Go..
CI
2018Astellas Pharma Inc. and Kotobuki Pharmaceutical Co., Ltd. Announces Approval..
CI
2018Iota Biosciences, Inc. announced that it has received $15.000001 million in f..
CI
2018Astellas Pharma Inc. and Pfizer Announce Positive Top-Line Results from Phase..
CI
2018Astellas Pharma Inc. acquired an unknown majority stake in Potenza Therapeuti..
CI
2018Astellas Announces Promotion of Lei Ding to Vice President, Payer Strategy, C..
CI
2018Astellas Pharma Inc. Launches XOSPATA« (Gilteritinib) in U.S for the Treatmen..
CI
2018Astellas Pharma Inc. Presents Updated Results from Phase 1 Study of Gilteriti..
CI
2018Eurofins Pharma Services Lux Holding SARL completed the acquisition of Astell..
CI
2018U.S. FDA Approves Astellas Pharma Inc.’s XOSPATA (gilteritinib) for Adult Pat..
CI
2018ASTELLAS PHARMA : gets U.S. nod for blood cancer treatment
RE
2018BIG PHARMA LEAVES BIG GAPS : drugmakers urged to do more for poor
RE
2018Astellas Pharma Inc. to Present New Data on Gilteritinib in Multiple Populati..
CI
2018Astellas Pharma Inc. Reports Consolidated Earnings Results for the Six Months..
CI
2018Astellas Pharma Inc. Announces Construction of New Research, Development and ..
CI
2018FibroGen, Inc. and Astellas Pharma Inc. Announce Presentation of Data from Tw..
CI
2018Astellas Receives European Approval for Xtandi(Enzalutamide) for Adult Men wi..
CI
2018Cytokinetics, Incorporated and Astellas Pharma Inc. Provide Updates Regarding..
CI
2018Astellas Pharma Inc. Submits New Drug Application in Japan of Roxadustat for ..
CI
2018ASTELLAS PHARMA INC : Ex-dividend day for interim dividend
FA
2018Anaeropharma Science Inc. Signs Collaborative Research Agreement with Astella..
CI
2018Astellas Pharma Inc. and Amgen Astellas Biopharma K.K. Receives Approval for ..
CI
2018ASTELLAS PHARMA : Receives Positive CHMP Opinion for XTANDI™ (enzalutamide..
PU
2018ASTELLAS PHARMA : BLINCYTO« FOR DRIP INFUSION 35 μg APPROVED IN JAPAN FOR THE..
PU
2018Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI« (enzalutamide..
CI
2018ASTELLAS PHARMA : Announces Approval in Japan for XOSPATA« 40 mg Tablets for the..
PU
2018ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares
PU
2018Astellas Receives Approval in Japan for Xospata 40 Mg Tablets for the Treatme..
CI
2018Tranche Update on Astellas Pharma Inc.'s Equity Buyback Plan announced on May..
CI
2018Astellas Pharma Inc.'s Equity Buyback announced on May 31, 2018 has expired w..
CI
2018ASTELLAS PHARMA : Announces Positive Topline Results for Global Phase 3 Trial of..
PU
2018Astellas Pharma Inc. Announces Positive Topline Results for Global Phase 3 Tr..
CI
2018ASTELLAS PHARMA : Announces Launch of Dafclir« Tablets for the Treatment of Infe..
PU
2018ASTELLAS PHARMA : Gene Therapy Research Institution and Astellas Executes Option..
PU
2018ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
PU
2018Astellas Promotes Rodrigo Fernandez to Vice President, Latin America
CI
2018ASTELLAS PHARMA : Pfizer and Astellas Amend Clinical Research Protocols for Two ..
PU
2018Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials ..
CI
2018Pfizer, Astellas revise two cancer drug trial protocols to speed up results
RE
2018ASTELLAS PHARMA : Approval of Linzess« Tablets 0.25 mg in Japan for Additional I..
PU
2018Astellas Promotes David Abbott to National Vice President Key Account Managem..
CI
2018ASTELLAS PHARMA : Announces Acquisition of Quethera - Acquisition furthers ' com..
PU
2018Astellas Pharma Inc. acquired Quethera Limited from Parkwalk Advisors Ltd, UK..
CI
2018ASTELLAS PHARMA : Application for Supplemental Indication Filed for Hypercholest..
PU
2018ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
PU
2018Astellas Pharma Inc. Reports Consolidated Earnings Results for the First Quar..
CI
Prev.1  2  3  4   5  6  7  8  9  10Next
Upcoming event on ASTELLAS PHARMA INC.